DASH Dietary Pattern and Cardiometabolic Outcomes: An Umbrella Review of Systematic Reviews and Meta-Analyses.
Chiavaroli L, Viguiliouk E, Nishi SK, Blanco Mejia S, Rahelić D, Kahleová H, Salas-Salvadó J, Kendall CW, Sievenpiper JL. · 2019
Read DASH Dietary Pattern and Cardiometabolic Outcomes: An Umbrella Review of Systematic Reviews and Meta-Analyses. by Chiavaroli L, Viguiliouk E, Nishi SK, Blanco Mejia S, Rahelić D, Kahleová H, Salas-Salvadó J, Kendall CW, Sievenpiper JL. (2019) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc6413235.txt.
Introduction
Chiavaroli and co-authors present an umbrella review in Nutrients on the DASH diet. DASH stresses fruit, vegetables, whole grains, nuts, and low-fat dairy. It limits salt, red meat, sweets, and sugary drinks, and is widely advised for heart health.
An umbrella review joins many past systematic reviews into one verdict. The team graded proof on DASH and heart and metabolic outcomes. Work was done to update European diabetes guidance. Across reviews, DASH links to lower blood pressure and better metabolic markers. The authors sort which outcomes rest on strong proof and which on weak.
Catalog record
| CREATOR | Chiavaroli L, Viguiliouk E, Nishi SK, Blanco Mejia S, Rahelić D, Kahleová H, Salas-Salvadó J, Kendall CW, Sievenpiper JL. |
|---|---|
| YEAR | 2019 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 76 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
DASH Dietary Pattern and Cardiometabolic Outcomes: An Umbrella Review of Systematic Reviews and Meta-Analyses By Laura Chiavaroli, Effie Viguiliouk, Stephanie K Nishi, Sonia Blanco Mejia, Dario Rahelić, Hana Kahleová, Jordi Salas-Salvadó, Cyril WC Kendall, John L Sievenpiper Published in: Nutrients DOI: 10.3390/nu11020338 ABSTRACT Background: The Dietary Approaches to Stop Hypertension (DASH) dietary pattern, which emphasizes fruit, vegetables, fat-free/low-fat dairy, whole grains, nuts and legumes, and limits saturated fat, cholesterol, red and processed meats, sweets, added sugars, salt and sugar-sweetened beverages, is widely recommended by international diabetes and heart association guidelines. Objective: To summarize the available evidence for the update of the European Association of the Study of Diabetes (EASD) guidelines, we conducted an umbrella review of existing systematic reviews and meta-analyses using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) approach of the relation of the DASH dietary pattern with cardiovascular disease and other cardiometabolic outcomes in prospective cohort studies and its effect on blood pressure and other cardiometabolic risk factors in controlled trials in individuals with and without diabetes. Methods: MEDLINE and EMBASE were searched through 3 January 2019. We included systematic reviews and meta-analyses assessing the relation of the DASH dietary pattern with cardiometabolic disease outcomes in prospective cohort studies and the effect on cardiometabolic risk factors in randomized and non-randomized controlled trials. Two independent reviewers extracted relevant data and assessed the risk of bias of individual studies. The primary outcome was incident cardiovascular disease (CVD) in the prospective cohort studies and systolic blood pressure in the controlled trials. Secondary outcomes included incident coronary heart disease, stroke, and diabetes in prospective cohort studies and other established cardiometabolic risk factors in controlled trials. If the search did not identify an existing systematic review and meta-analysis on a pre-specified outcome, then we conducted our own systematic review and meta-analysis. The evidence was summarized as risk ratios (RR) for disease incidence outcomes and mean differences (MDs) for risk factor outcomes with 95% confidence intervals (95% CIs). The certainty of the evidence was assessed using GRADE. Results: We identified three systematic reviews and meta-analyses of 15 unique prospective cohort studies (n = 942,140) and four systematic reviews and meta-analyses of 31 unique controlled trials (n = 4,414) across outcomes. We conducted our own systematic review and meta-analysis of 2 controlled trials (n = 65) for HbA1c. The DASH dietary pattern was associated with decreased incident cardiovascular disease (RR, 0.80 (0.76–0.85)), coronary heart disease (0.79 (0.71–0.88)), stroke (0.81 (0.72–0.92)), and diabetes (0.82 (0.74–0.92)) in prospective cohort studies and decreased systolic (MD, −5.2 mmHg (95% CI, −7.0 to −3.4)) and diastolic (−2.60 mmHg (−3.50 to −1.70)) blood pressure, Total-C (−0.20 mmol/L (−0.31 to −0.10)), LDL-C (−0.10 mmol/L (−0.20 to −0.01)), HbA1c (−0.53% (−0.62, −0.43)), fasting blood insulin (−0.15 μU/mL (−0.22 to −0.08)), and body weight (−1.42 kg (−2.03 to −0.82)) in controlled trials. There was no effect on HDL-C, triglycerides, fasting blood glucose, HOMA-IR, or CRP. The certainty of the evidence was moderate for SBP and low for CVD incidence and ranged from very low to moderate for the secondary outcomes. Conclusions: Current evidence allows for the conclusion that the DASH dietary pattern is associated with decreased incidence of cardiovascular disease and improves blood pressure with evidence of other cardiometabolic advantages in people with and without diabetes. More research is needed to improve the certainty of the estimates. 1. INTRODUCTION Cardiovascular disease (CVD) continues to be a leading cause of mortality in people with and without diabetes globally [1,2,3]. Clinical practice guidelines recommend dietary strategies as the cornerstone of therapy to prevent and manage cardiovascular disease [4,5,6,7,8,9]. The dietary approaches to stop hypertension (DASH) dietary pattern, which emphasizes fruit, vegetables, fat-free/low-fat dairy, whole grains, nuts and legumes, and limits total and saturated fat, cholesterol, red and processed meats, sweets, added sugars, and sugar-sweetened beverages, was originally developed through research sponsored by the US National Institutes of Health (NIH) to treat hypertension without medication and successfully demonstrated a clinically meaningful blood pressure lowering effect [10]. In addition to reducing blood pressure, the DASH dietary pattern has since been shown to have a decreasing effect on low-density lipoprotein-cholesterol (LDL-C) among other cardiometabolic risk factors in randomized controlled trials and be associated with reductions in diabetes and cardiovascular mortality in prospective cohort studies [11,12,13]. These benefits of the DASH dietary pattern have been recognized by general dietary guidelines from the U.S.-based National Heart, Lung, and Blood Institute (NHLBI) and the United States Department of Agriculture (USDA) [14]. International diabetes [7,15] and cardiovascular [6,16,17] clinical practice guidelines have also recommended the DASH dietary pattern for cardiovascular risk reduction. The European Association for the Study of Diabetes (EASD), however, has not reviewed the evidence or made specific recommendations regarding the DASH dietary pattern in its clinical practice guidelines for nutrition therapy. To update current recommendations, the Diabetes and Nutrition Study Group (DNSG) of the EASD commissioned an umbrella review of existing systematic reviews and meta-analyses using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) approach to summarize the available evidence of the relation of the DASH dietary pattern with diabetes and cardiovascular outcomes in prospective cohort studies and its effect on blood pressure and other established cardiometabolic risk factors in randomized and non-randomized controlled trials. 2. MATERIALS AND METHODS 2.1. Design Public health policy and clinical practice guidelines are established with the use of systematic reviews and meta-analyses of controlled trials and prospective cohort studies, which are regarded as the best levels of evidence. We thus identified the most recent systematic reviews and meta-analyses assessing the relationships of the DASH dietary pattern with incident cardiometabolic diseases in prospective cohort studies and on cardiometabolic risk factors in randomized and non-randomized controlled trials in individuals with and without diabetes. The umbrella review was conducted according to the principals of the Cochrane Handbook for Systematic Reviews of Interventions [18] and the GRADE handbook [19] with reporting according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) [20]. The study protocol was registered (clinicaltrials.gov identifier, NCT03542370). 2.2. Study selection The databases Medline and Embase were searched from inception through 3 January 2019 using the search terms “dietary approaches to stop hypertension” or “DASH” and “meta-analysis” (Supplemental Table S1). If the search of systematic reviews and meta-analyses did not identify an existing systematic review and meta-analysis on any of the pre-specified outcomes below, then we conducted our own systematic review and meta-analysis in which studies were eligible if the intervention was a DASH dietary pattern and the outcomes of interest were reported. 2.3. Data extraction Two independent reviewers extracted relevant data from each included systematic review and meta-analysis and from invidual studies if we had to conduct our own systmatic review and meta-analysis. 2.4. Risk of Bias Assessment The quality of the individual studies contained in each systematic review and meta-analysis was assessed by the two independent reviewers. Study characteristics were extracted and risk of bias assessments were performed using either the New Castle Ottawa score [21] for the prospective cohort studies or the Cochrane Risk of Bias Tool [22] for the controlled trials. 2.5. Outomes The primary outcome was incident CVD in the prospective cohort studies and SBP in the controlled trials. Secondary outcomes included incident coronary heart disease